BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 22465225)

  • 1. Tumor tissue inhibitor of metalloproteinases-1 (TIMP-1) in hormone-independent breast cancer might originate in stromal cells, and improves stratification of prognosis together with nodal status.
    Kuvaja P; Hulkkonen S; Pasanen I; Soini Y; Lehtonen S; Talvensaari-Mattila A; Pääkkö P; Kaakinen M; Autio-Harmainen H; Hurskainen T; Lehenkari P; Turpeenniemi-Hujanen T
    Exp Cell Res; 2012 Jun; 318(10):1094-103. PubMed ID: 22465225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases.
    Ree AH; Florenes VA; Berg JP; Maelandsmo GM; Nesland JM; Fodstad O
    Clin Cancer Res; 1997 Sep; 3(9):1623-8. PubMed ID: 9815852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced mRNA expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in breast carcinomas is correlated with adverse prognosis.
    Nakopoulou L; Giannopoulou I; Stefanaki K; Panayotopoulou E; Tsirmpa I; Alexandrou P; Mavrommatis J; Katsarou S; Davaris P
    J Pathol; 2002 Jul; 197(3):307-13. PubMed ID: 12115876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is tissue inhibitor of metalloproteinase-1 a new prognosticator for breast cancer? An analysis of 266 cases.
    Neri A; Megha T; Bettarini F; Tacchini D; Mastrogiulio MG; Marrelli D; Pinto E; Tosi P
    Hum Pathol; 2012 Aug; 43(8):1184-91. PubMed ID: 22397869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of tissue inhibitor of metalloproteinase-2 with proliferative activity and patients' survival in breast cancer.
    Nakopoulou L; Katsarou S; Giannopoulou I; Alexandrou P; Tsirmpa I; Panayotopoulou E; Mavrommatis J; Keramopoulos A
    Mod Pathol; 2002 Jan; 15(1):26-34. PubMed ID: 11796838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tissue inhibitor of metalloproteinases-1 in breast cancer.
    Würtz SØ; Schrohl AS; Sørensen NM; Lademann U; Christensen IJ; Mouridsen H; Brünner N
    Endocr Relat Cancer; 2005 Jun; 12(2):215-27. PubMed ID: 15947098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alpha- and beta-adrenergic receptor (AR) protein expression is associated with poor clinical outcome in breast cancer: an immunohistochemical study.
    Powe DG; Voss MJ; Habashy HO; Zänker KS; Green AR; Ellis IO; Entschladen F
    Breast Cancer Res Treat; 2011 Nov; 130(2):457-63. PubMed ID: 21298476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Podoplanin-expressing cancer-associated fibroblasts are associated with poor prognosis in invasive breast cancer.
    Schoppmann SF; Berghoff A; Dinhof C; Jakesz R; Gnant M; Dubsky P; Jesch B; Heinzl H; Birner P
    Breast Cancer Res Treat; 2012 Jul; 134(1):237-44. PubMed ID: 22350732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitotic activity and bone marrow micrometastases have independent prognostic value in node positive breast cancer patients.
    Gilje B; Nordgård O; Tjensvoll K; Janssen EA; Søiland H; Smaaland R; Baak JP
    Breast Cancer Res Treat; 2011 Jul; 128(1):137-46. PubMed ID: 21476002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stromal expression of CD10 in invasive breast carcinoma: a new predictor of clinical outcome.
    Iwaya K; Ogawa H; Izumi M; Kuroda M; Mukai K
    Virchows Arch; 2002 Jun; 440(6):589-93. PubMed ID: 12070597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
    Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Expression and clinical significance of MMP-2, MMP-9,TIMP-1, and TIMP-2 in breast carcinoma].
    Fan SQ; Wei QY; Li MR; Zhang LQ; Liang QC
    Ai Zheng; 2003 Sep; 22(9):968-73. PubMed ID: 12969531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COX-2 expression in human breast carcinomas: correlation with clinicopathological features and prognostic molecular markers.
    Miglietta A; Toselli M; Ravarino N; Vencia W; Chiecchio A; Bozzo F; Motta M; Torchio B; Bocca C
    Expert Opin Ther Targets; 2010 Jul; 14(7):655-64. PubMed ID: 20536410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer.
    Sáez R; Molina MA; Ramsey EE; Rojo F; Keenan EJ; Albanell J; Lluch A; García-Conde J; Baselga J; Clinton GM
    Clin Cancer Res; 2006 Jan; 12(2):424-31. PubMed ID: 16428482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R; Schaaf A
    Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathological parameters and biological markers predicting non-sentinel node metastasis in sentinel node-positive breast cancer patients.
    Kwon Y; Ro J; Kang HS; Kim SK; Hong EK; Khang SK; Gong G; Ro JY
    Oncol Rep; 2011 Apr; 25(4):1063-71. PubMed ID: 21258771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent.
    Gouyer V; Conti M; Devos P; Zerimech F; Copin MC; Créme E; Wurtz A; Porte H; Huet G
    Cancer; 2005 Apr; 103(8):1676-84. PubMed ID: 15754326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the hepatocellular carcinomas].
    Wei QY; Wu YQ; Fan SQ
    Hunan Yi Ke Da Xue Xue Bao; 2003 Jun; 28(3):212-6. PubMed ID: 14653069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicentric and multifocal versus unifocal breast cancer: is the tumor-node-metastasis classification justified?
    Weissenbacher TM; Zschage M; Janni W; Jeschke U; Dimpfl T; Mayr D; Rack B; Schindlbeck C; Friese K; Dian D
    Breast Cancer Res Treat; 2010 Jul; 122(1):27-34. PubMed ID: 20454925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Significance of TIMP-1 and nm-23 expressions in HER-2-positive breast cancer].
    Liu J; Yang YF; Fu XL; Yu Y; Gu L
    Zhonghua Zhong Liu Za Zhi; 2012 Aug; 34(8):600-4. PubMed ID: 23158994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.